Ascierto, Paolo A.
Agarwala, Sanjiv S.
Eggermont, Alexander
Gershenwald, Jeffrey E.
Grob, Jean-Jacques
Hamid, Omid
Michielin, Olivier
Postow, Michael
Puzanov, Igor
Zarour, Hassane M.
Caracò, Corrado
Testori, Alessandro
Article History
Received: 1 April 2020
Accepted: 9 April 2020
First Online: 16 April 2020
Ethics approval and consent to participate
: Not applicable.
: :Not applicable.
: Paolo A. Ascierto (PAA): consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD. Sanjiv S. Agarwala (SSA): declares he has not conflict of interest to report. Alexander Eggermont (AE): Honoraria for consultant activities over the last 2 years for: BMS, Biocad, BioInvent, CatalYm, GSK, ISA Pharmaceuticals, Merck/MSD, Nektar, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sellas, SkylineDx; Equity: RiverD, SkylineDx, Theranovir. Jeffrey E. Gershenwald (JEG): consultant and/or advisory board for Merck, Syndax, Novartis, BMS. Jean-Jacques Grob (JJG): Advisor for Novartis, Roche, BMS, MSD, Amgen, Pierre Fabre, Merck/Pfizer, Sanofi, SunPharma. Omid Hamid (OH): Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono. Expert Testimony: Genentech. Other: Bristol-Meyers Squibb, Novartis, Array. Olivier Michielin (OM): Honoraria as speaker, consultancy or advisory role: Bristol-Myers Squibb, Roche, Amgen, Merck Sharp & Dohme, Novartis, GlaxoSmithKline, Pierre-Fabre. Research Funding: Bristol-Myers Squibb, Merck Sharp & Dohme and Amgen. Stock ownership: none. Michael Postow (MP): consulting fees: BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro. Honoraria: BMS and Merck. Institutional Support: RGenix, Infinity, BMS, Merck, Array BioPharma, Novartis, AstraZeneca. Igor Puzanov (IP): consultant, research funding to institutional Amgen, Nektar, ADC, Idera Pharmaceutical. Hassane M. Zarour (HMZ): Research Contracts: BMS, Merck, Checkmate and Tesaro. Corrado Caracò (CC): declares he has not conflict of interest to report. Alessandro Testori (AT): declares he has not conflict of interest related to the topics in this paper; received travel support for meetings from Agenus.